Glucocorticoid-Induced Osteoporosis: New Insights into the Pathophysiology and Treatments
Purpose of this Review
The goal of the review is to provide an updated understanding of the pathophysiology of glucocorticoid-induced osteoporosis and treatment recommendations.
Glucocorticoids reduce osteoblast and osteocyte lifespan and activity and reduce the vascularity of the bone that together may explain the greater reductions in bone strength than those of bone mass. Treatments with parathyroid hormone fragments appear to reverse glucocorticoid-induced bone loss and fracture risk partially through maintaining bone vascularity and bone strength.
This review identifies how glucocorticoid anti-osteogenic and vascular effects together may reduce bone strength. It also provides guidance to clinicians on rationale treatment for glucocorticoid-induced osteoporosis.
KeywordsGlucocorticoids Bone cells Bone vascularity Osteonecrosis Parathyroid hormone
Compliance with Ethical Standards
Conflict of Interest
Nancy Lane reports having a patent (LLP2A-ale) issued.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 4.Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum. 2008;58:1674–86. https://doi.org/10.1002/art.23954.CrossRefPubMedCentralGoogle Scholar
- 7.Lane NE, Yao W, Balooch M, Nalla RK, Balooch G, Habelitz S, et al. Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res. 2006;21(3):466–76. https://doi.org/10.1359/JBMR.051103.CrossRefGoogle Scholar
- 10.Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102(2):274–82. https://doi.org/10.1172/JCI2799.CrossRefPubMedCentralGoogle Scholar
- 14.Mohan G, Lay EY, Berka H, Ringwood L, Kot A, Chen H, et al. A novel hybrid compound LLP2A-Ale both prevented and rescued the osteoporotic phenotype in a mouse model of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2017;100(1):67–79. https://doi.org/10.1007/s00223-016-0195-6.CrossRefGoogle Scholar
- 16.Lane NE, Mohan G, Yao W, Shidara K, Lay YE, Junjing J, et al. Prevalence of glucocorticoid induced osteonecrosis in the mouse is not affected by treatments that maintain bone vascularity. Bone Reports. 2018;9:181–9.Google Scholar
- 17.Jiang L, Zhang W, Wei L, Zhou Q, Yang G, Qian N, et al. Early effects of parathyroid hormone on vascularized bone regeneration and implant osseointegration in aged rats. Biomaterials. 2018;179:15–28. https://doi.org/10.1016/j.biomaterials.2018.06.035.CrossRefGoogle Scholar
- 21.• Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res. 2017;69(8):1095–110. https://doi.org/10.1002/acr.23279. Guidelines for the treatment of glucocorticoid-induced osteoporosis were revised. The methodology utilized was case based and recommendations are made for young, middle age, and older men and women. CrossRefGoogle Scholar
- 22.Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998;339(5):292–9. https://doi.org/10.1056/NEJM199807303390502.CrossRefGoogle Scholar
- 24.Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, et al. HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of GIOP (HORIZON): a multicenter, double-blind, double-dummy, randomized controlled trial. Lancet. 2009;373(9671):1253–63. https://doi.org/10.1016/S0140-6736(09)60250-6.CrossRefGoogle Scholar
- 25.Yao W, Cheng Z, Pham A, Busse C, Zimmermann EA, Ritchie RO, et al. Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum. 2008;58(11):3485–97. https://doi.org/10.1002/art.23954.CrossRefPubMedCentralGoogle Scholar
- 28.• Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018;6(6):445–54. https://doi.org/10.1016/S2213-8587(18)30075-5. This randomized, double blind, active control study demonstrated that in glucocorticoid-treated subjects, denosumab increased bone mass at the lumbar spine after 12 months significantly more than subjects treated with risedronate. This result was observed in both subjects initiating glucocorticoid treatment or chronic glucocorticoid therapy. CrossRefGoogle Scholar
- 29.• Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33(2):190–8. https://doi.org/10.1002/jbmr.3337. This post hoc analysis of the extension of the phase 3 FREEDOM trial determined that subjects that discontinued denosumab had an increase risk of vertebral fractures that was similar to the untreated subjects. Also, many of the subjects that had an incident vertebral fracture after discontinuation of denosumab had multiple vertebral fractures, and subjects with a prior fracture had a greater risk. These results led to the recommendation that subjects discontinuing denosumab should transition to another anti-resorptive agent for a period of time.CrossRefGoogle Scholar